The reduced vision in RP can be progressive photoreceptor cell death and treatable complications of RP, including cataractand macular edema. The major symptom of cataract is glare, especially in bright light. The cataract surgery time in RP is earlier than age-related cataract, with an average at 30 to 59 years old. The potential risks of cataract surgery, for example, ocular inflammation and increased eye pressure play a role in RP progression. During photoreceptor cell death, inflammatory cells are activated by releasing ...Read more
This 36-year-old female patient got diagnose with RP 7 years ago. She has lost about 80% central vision and 85% peripheral vision, she is using a walking stick and has registered legally blind. We have just received her brother’s message about the patient’s improvements in her vision since taking StemActiv. Less tiredness in the eyes.She used to see yellow squiggly lines in her vision between 8-10 times daily. Now she is reporting that she sees it around 1-2 times daily.Peripheral vision has ...Read more
This 65-year-old male patient has late-stage RP, his vision acuity was quite poor, he couldn’t go outside without somebody else help. After one year of continuous StemActiv treatment, his vision got tremendous improvement, fundus check shows the dark spots on his retina have reduced, OCT shows his retina thickness and optic nerve function gets normal. OCT after treatment: If you want to slow down your vision loss process, restore and even improve your vision function, please order the StemActiv treatment package on: https://www.restorevisionherbs.com/shop_stemactiv_product/Read more
Inflammation, oxidative stress and poor ocular circulation are the top three factors that accelerate progressive vision loss in RP. Inflammation and optic cells death are tightly interconnected. Studies propose that inflammation is a consequence of the photoreceptor degeneration triggered by genetic defects. During photoreceptor cell death, inflammatory cells are activated by releasing inflammatory substances that contribute to rod and cone cell death. This eventually accelerates vision loss. While there are still no effective treatments for most degenerative retinal disorders, except for RPE65 ...Read more
Retinitis Pigmentosa (RP) is a devastating eye disease and at present, there are no known treatment options that can alter the rate of vision loss and eventual blindness. In a series of studies in animal models, the effects of exposing cones in the periphery of the retina to a large excess of oxygen results in progressive oxidative damage to cone photoreceptors and cone cell death. Cone cell death gradually spreads from the periphery of the retina toward its center, narrowing the visual ...Read more
On August 9th, 2021, recombinant adeno-associated virus vector carrying human CYP4V2 gene has obtained Orphan Drug Designations and Approvals by the US FDA. This gene therapy is offered by China Gene technology. It brings hope for RP patients with the gene mutation of CYP4V2, which is also called Bietti crystalline dystrophy. Retinitis pigmentosa, congenital macular dystrophy, optic nerve atrophy and other congenital hereditary eye disorders are like a train rushing to the darkness. If not treated, they will eventually lead to blindness. Gene ...Read more
Comparison of the Latest Stem Cell Therapies for RP Stem cell represents the most promising strategy for RP and other retinal diseases in the near future, and therapeutics assisted by gene techniques, neuroprotective compounds and artificial devices can be applied to fulfil the clinical needs for different kinds of retinal diseases patients. Till now, retinal progenitor cells (RPCs), induced pluripotent stem cells (iPS) and mesenchymal stem cells (MSCs) have finished early-stage clinical trials since they can all differentiate into RPE, photoreceptors or ...Read more
Gene therapy, in which we have very high expectations to cure genetic disorders, is currently being translated from preclinical assays to the clinical practice for retinal degeneration diseases, with successful achievement up till now for the LCA, due to mutations in the RPE65 gene. This gave hope to cure RP of different genetic origins.
Currently, our gene therapy research team is focusing on gene replacement therapy, gene editing therapy and optogenetic gene therapy. With these promising therapies, though, comes relevant challenges.
Over 300 ...Read more
Compared with gene therapy, stem cell treatment is more widely used for all kinds of gene mutation types of RP. Therefore, the research and development costs are more affordable in China. Stem cell treatment is just like we cannot cure hypertension, but we can manage the blood pressure and prevent stroke and other cardiovascular accidents via effective medication.
Eyes are immune privilege organ, stem cells will not be rejected when it’s inside the eyes. We can track where the stem cell goes ...Read more
Eleven advanced RP patients, with no light perception, or just perception of light in the study eye, and no better than counting fingers in the fellow eye, received intravitreal optogenetics gene therapy. They improved visual acuity from baseline at 16 weeks.
The single intravitreal injection targets bipolar cells instead of retinal ganglion cells. Optogenetics gene therapy turns bipolar cells into light-sensing activated neurons in response to light, making them the new photoreceptors of the retina.
Methods: Totally eleven patients were enrolled in the ...Read more